GlobeNewswire: Kane Biotech Inc. Contains the last 10 of 310 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:21:18ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852741/0/en/Kane-Biotech-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=37293Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results2024-03-26T20:05:00Z<![CDATA[WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results.]]>https://www.globenewswire.com/news-release/2024/03/20/2849367/0/en/Kane-Biotech-Extends-Exclusivity-Period-on-its-Offer-for-its-Interest-in-STEM-Animal-Health.html?f=22&fvtc=4&fvtv=37293Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health2024-03-20T12:30:00Z<![CDATA[WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024.]]>https://www.globenewswire.com/news-release/2024/03/19/2848971/0/en/Kane-Biotech-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-26-2024-Conference-Call-to-Follow.html?f=22&fvtc=4&fvtv=37293Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow2024-03-19T20:10:00Z<![CDATA[WINNIPEG, Manitoba, March 19, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2023 financial results after market close on Tuesday, March 26, 2024.]]>https://www.globenewswire.com/news-release/2024/03/08/2843134/0/en/Kane-Biotech-Receives-Bioscience-Association-Manitoba-Company-of-the-Year-Award.html?f=22&fvtc=4&fvtv=37293Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award2024-03-08T14:00:00Z<![CDATA[WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award.]]>https://www.globenewswire.com/news-release/2024/02/22/2833612/0/en/Dr-Robert-Huizinga-Elected-to-the-Kane-Biotech-Board-and-Appointed-Executive-Chair.html?f=22&fvtc=4&fvtv=37293Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair2024-02-22T13:00:00Z<![CDATA[WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company.]]>https://www.globenewswire.com/news-release/2024/01/31/2821122/0/en/Kane-Biotech-Files-New-Patent-on-revyve-Antimicrobial-Wound-Gel-Spray.html?f=22&fvtc=4&fvtv=37293Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray2024-01-31T13:30:00Z<![CDATA[Kane will introduce its unique spray gel at the Boswick Burn and Wound Care Symposium Kane will introduce its unique spray gel at the Boswick Burn and Wound Care Symposium]]>https://www.globenewswire.com/news-release/2024/01/25/2817201/0/en/Kane-Biotech-to-Present-its-revyve-Antimicrobial-Wound-Gel-at-Boswick-Burn-and-Wound-Care-Symposium.html?f=22&fvtc=4&fvtv=37293Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium2024-01-25T17:03:38Z<![CDATA[WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium.]]>https://www.globenewswire.com/news-release/2024/01/18/2811977/0/en/Kane-Biotech-Announces-Special-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=37293Kane Biotech Announces Special Meeting of Shareholders2024-01-18T21:30:00Z<![CDATA[WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be filed on SEDAR+ by the Company in due course.]]>https://www.globenewswire.com/news-release/2023/12/29/2802146/0/en/Kane-Biotech-Announces-Correction-to-Press-Release.html?f=22&fvtc=4&fvtv=37293Kane Biotech Announces Correction to Press Release2023-12-29T19:33:40Z<![CDATA[WINNIPEG, Manitoba, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023. The maturity date of the Company’s amended and restated credit facility between Pivot I Financial Limited Partnership and the Company dated August 31, 2021, as amended, has been extended to March 31, 2024, not March 31, 2023 as stated in the release.]]>https://www.globenewswire.com/news-release/2023/12/28/2801850/0/en/Kane-Biotech-Announces-Amendment-to-its-Credit-Facility.html?f=22&fvtc=4&fvtv=37293Kane Biotech Announces Amendment to its Credit Facility2023-12-28T21:05:00Z<![CDATA[WINNIPEG, Manitoba, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of the Company’s amended and restated credit facility between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”) by extending the maturity date of the Credit Facility from November 30, 2023 to March 31, 2023. In addition, the parties agreed that from December 1, 2023 until maturity, interest accrued on each advance under the Credit Facility thereafter shall be payable monthly in arrears rather than being added to the principal amount of the Credit Facility and repaid at maturity.]]>